Erwinia asparaginase in pediatric acute lymphoblastic leukemia (Q38040418)

27 August 2017

Erwinia asparaginase in pediatric acute lymphoblastic leukemia (English)

1 reference

27 August 2017

2

Nita Seibel

1 reference

27 August 2017

Wanda Salzer

1

1 reference

PubMed ID

22946493

27 August 2017

Malcolm Smith

series ordinal

3

1 reference

PubMed ID

22946493

27 August 2017

language of work or name

English

0 references

publication date

4 September 2012

1 reference

Expert Opinion on Biological Therapy

27 August 2017

1 reference

27 August 2017

12

1 reference

27 August 2017

1407-1414

1 reference

27 August 2017

10

1 reference

Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia.

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

l-Asparaginase resistance in human leukemia—Asparagine synthetase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Duration and severity of fatty metamorphosis of the liver following L-asparaginase therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Toxicity of E. coli L-asparaginase in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

Acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.718327

10.1517/14712598.2012.718327

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22946493